Drugs / ADH-1
ADH-1
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01825603 | Apr 2013 → Jun 2017 | ampulla of vater adenocarcinoma, gallbladder adenocarcinoma, hilar cholangiocarcinoma, pancreatic adenocarcinoma | University of Nebraska | Completed | No outcome recorded |
| Phase 1 | NCT00390676 | Nov 2006 → Nov 2009 | neoplasm | Adherex Technologies, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00421811 | Apr 2007 → Mar 2009 | neoplasm | Adherex Technologies, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00265057 | Jun 2005 → Jan 2008 | neoplasm | Adherex Technologies, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00225550 | — | neoplasm | Adherex Technologies, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00264433 | — | neoplasm | Adherex Technologies, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADH-1 | “Study of ADH-1 Given Intravenously to Patients With Solid Tumors” NCT00265057 ↗5“ADH-1 blocks N-cadherin.” NCT00225550 ↗ “ADH-1 blocks N-cadherin.” NCT00390676 ↗ “ADH-1 blocks N-cadherin.” NCT00264433 ↗ |
| Known as | Cys-his-ala-val-cys | ChEMBL registry synonym — accepted as the source's own label CHEMBL3818130 ↗ |
| Known as | Exherin | “Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Daily for 5 Consecutive Days by Intravenous Infusion” NCT00225550 ↗ |
| Known as | NSC-729477 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3818130 ↗ |
| Action | Inhibit | “ADH-1 blocks N-cadherin.” NCT00225550 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3818130 ↗ |
| Route | Intravenous | “by Intravenous Infusion” NCT00225550 ↗ |